New obesity drug combo shows promise in Mid-Stage trial

NCT ID NCT06577090

Ongoing Disease control Sponsor: Skye Bioscience, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new injectable drug called nimacimab, given weekly, to see if it helps overweight or obese adults lose weight. Some participants will receive nimacimab alone, others will get it together with semaglutide (a known weight-loss drug), and some will receive a placebo. The trial involves 136 people and aims to measure changes in body weight and waist size over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

ACCEL Research Sites

Atlanta, Georgia, 30342, United States
Accellacare of Wilmington

Wilmington, North Carolina, 28401, United States
ActivMed Practices & Research

Portsmouth, New Hampshire, 03801, United States
Be Well Clinical Studies

Lincoln, Nebraska, 68516, United States
Be Well Clinical Studies

Round Rock, Texas, 78681, United States
Center for Advanced Research & Education

Gainesville, Georgia, 30501, United States
Charlottesville Medical Research

Charlottesville, Virginia, 22911, United States
Chase Medical Research, LLC

Waterbury, Connecticut, 06708, United States
Diablo Clinical Research, Inc.

Walnut Creek, California, 94598, United States
L-MARC Research Center

Louisville, Kentucky, 40213, United States
Lillestol Research, LLC

Fargo, North Dakota, 58104, United States
Palm Research Center

Las Vegas, Nevada, 89148, United States
Pinnacle Research Group

Anniston, Alabama, 36207, United States
Rainier Clinical Research Center

Renton, Washington, 98057, United States
Velocity Clinical Research, Dallas

Dallas, Texas, 75230, United States
Weill Cornell Medicine

New York, New York, 11375, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.